← Evidence map

ReviewCureus2026

Evaluating Clinical Efficacy and Survival Outcomes of Crizotinib in Anaplastic Lymphoma Kinase (ALK)-Positive Non-small Cell Lung Cancer (NSCLC): A Systematic Review and Meta-Analysis.

Hunter W Brady et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.

Not cited yet

Evaluating Clinical Efficacy and Survival Outcomes of Crizotinib in Anaplastic Lymphoma Kinase (ALK)-Positive Non-small Cell Lung Cancer (NSCLC): A Systematic Review and Meta-Analysis. | Socratic